Next Article in Journal
XRN2 Links RNA:DNA Hybrid Resolution to Double Strand Break Repair Pathway Choice
Next Article in Special Issue
Identification of Novel microRNA Prognostic Markers Using Cascaded Wx, a Neural Network-Based Framework, in Lung Adenocarcinoma Patients
Previous Article in Journal
Sex and Gender Disparities in Melanoma
Previous Article in Special Issue
Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance
Article

Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer

1
Discipline of Surgery, School of Medicine, Lambe Institute for Translational Research, National University of Ireland Galway, Galway H91 YR71, Ireland
2
School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway H91 TK33, Ireland
3
Department of Medical Oncology, Galway University Hospital, Galway H71 YR71, Ireland
4
Department of Biological Sciences, University of Limerick, Limerick V94 T9PX, Ireland
5
Centre for Chromosome Biology, School of Natural Science, National University of Ireland Galway, Galway H91 W2TY, Ireland
6
Cancer Trials Ireland, Innovation House, Old Finglas Road, Dublin D11 KXN4, Ireland
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(7), 1820; https://doi.org/10.3390/cancers12071820
Received: 14 May 2020 / Revised: 17 June 2020 / Accepted: 3 July 2020 / Published: 7 July 2020
(This article belongs to the Collection Cancer Biomarkers)
Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter, prospective study (CTRIAL-IE (ICORG) 10-11 study) evaluated circulating microRNA as novel non-invasive prognostic biomarkers of NACT response in breast cancer. Selected circulating microRNAs (Let-7a, miR-21, miR-145, miR-155, miR-195) were quantified from patients undergoing standard of care NACT treatment (n = 114) from whole blood at collected at diagnosis, and the association with NACT response and clinicopathological features evaluated. NACT responders had significantly lower levels of miR-21 (p = 0.036) and miR-195 (p = 0.017), compared to non-responders. Evaluating all breast cancer cases miR-21 was found to be an independent predictor of response (OR 0.538, 95% CI 0.308–0.943, p < 0.05). Luminal cancer NACT responders were found to have significantly decreased levels of miR-145 (p = 0.033) and miR-21 (p = 0.048), compared to non-responders. This study demonstrates the prognostic ability of miR-21, miR-195 and miR-145 as circulating biomarkers stratifying breast cancer patients by NACT response, identifying patients that will derive the maximum benefit from chemotherapy. View Full-Text
Keywords: breast; microRNA; neoadjuvant; chemotherapy; prognostic; biomarker breast; microRNA; neoadjuvant; chemotherapy; prognostic; biomarker
Show Figures

Figure 1

MDPI and ACS Style

McGuire, A.; Casey, M.-C.; Waldron, R.M.; Heneghan, H.; Kalinina, O.; Holian, E.; McDermott, A.; Lowery, A.J.; Newell, J.; Dwyer, R.M.; Miller, N.; Keane, M.; Brown, J.A.L.; Kerin, M.J. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers 2020, 12, 1820. https://doi.org/10.3390/cancers12071820

AMA Style

McGuire A, Casey M-C, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers. 2020; 12(7):1820. https://doi.org/10.3390/cancers12071820

Chicago/Turabian Style

McGuire, Andrew, Maire-Caitlin Casey, Ronan M. Waldron, Helen Heneghan, Olga Kalinina, Emma Holian, Ailbhe McDermott, Aoife J. Lowery, John Newell, Róisín M. Dwyer, Nicola Miller, Maccon Keane, James A.L. Brown, and Michael J. Kerin 2020. "Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer" Cancers 12, no. 7: 1820. https://doi.org/10.3390/cancers12071820

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop